2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Brain Neoplasms
12
Cognitive Dysfunction
4
Radiation Injuries
3
Neoplasms
3
Multiple Myeloma
3
Glioma
3
Breast Neoplasms
3
Lymphoma, B-Cell
2
Lymphoma
2
Glioblastoma
2
Fatigue
2
Colorectal Neoplasms
2
Astrocytoma
2
Triple Negative Breast Neoplasms
1
Stroke
1
Sarcoma
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Parkinson Disease
1
Osteosarcoma
1
Oligodendroglioma
1
Neurotoxicity Syndromes
1
Neurofibromatosis 1
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Meningioma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
Temozolomide
74
Radiotherapy
34
Carboplatin
21
Bevacizumab
18
Magnetic Resonance Spectroscopy
17
Irinotecan
16
Carmustine
16
Vincristine
14
Surgical Procedures, Operative
13
Filgrastim
13
Procarbazine
10
Erlotinib Hydrochloride
8
Cyclophosphamide
8
Peripheral Blood Stem Cell Transplantation
7
O(6)-benzylguanine
7
Lomustine
7
Etoposide
7
sargramostim
6
Imatinib Mesylate
6
Flucytosine
6
Cisplatin
6
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
6
temsirolimus
5
Vorinostat
5
Thiotepa
5
Radiotherapy, Intensity-Modulated
5
Radiation
5
Immunohistochemistry
5
Biopsy
5
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Oligodendroglioma
×
Neuropsychological Tests
×
Clear all
NCT02903784
2020-09-02
BNL
University Hospital, Montpellier
Phase NA
Completed
63 enrolled